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Purpose: To determine molecular mechanisms for the release of 11-cis-retinal from the binding pocket of cellular
retinaldehyde-binding protein (CRALBP).
Methods: Binding of CRALBP to lipid surfaces was assessed with a lipid-immunoblot assay. Lipids were presented to
CRALBP as small unilamellar vesicles (SUVs) consisting of phosphatidylcholine (PC) plus other lipids. Release of 9-
cis-retinal or 11-cis-retinal from CRALBP was measured with spectral and high performance liquid chromatography
(HPLC) assays based on the protection of the protein-bound retinal carbonyl group from reaction with NH2OH. The
electrostatic surface potential of CRALBP was calculated from a model of its structure using the program CCP4mg.
Results: Incubation of CRALBP·11-cis-retinal with lipids absorbed on nitrocellulose revealed binding to the acidic lipids,
phosphatidic acid (PA)>phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3]>phosphatidylserine (PS)> PI(4,5)P2 and
little or no binding to PC, phosphatidylethanolamine (PE), or PI(4)P. 11-cis-retinal was released during incubation of
CRALBP with SUVs consisting of PC plus 50 mol% PA but not during incubation with those composed of 100 mol%
PC. The efficacy of release of 9-cis-retinal or 11-cis-retinal from CRALBP by phospholipid-containing SUVs generally
paralleled that of the binding of CRALBP to the lipids (PA>PS>PI>>PC). Examination of the electrostatic surface potential
of the protein structure revealed a basic recess on one face of the protein, which may bind acidic lipids.
Conclusions: Our results identify the first physiologic substances that release 11-cis-retinal from CRALBP. PA and PS
are relatively minor membrane lipids that can be generated in the cytoplasmic leaflet of the plasma membrane in response
to various signal transduction pathways, where they could interact with cytosolic CRALBP. The mechanism for release
of retinal from CRALBP by acidic lipids remains to be determined but could involve binding of the acidic lipid in the 11-
cis-retinal binding site or to the positive basic recess on the protein surface. These results open a new facet in our
understanding of how CRALBP functions in the regeneration of visual pigments.
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Vertebrate  vision  could  not  be  maintained  without  a
mechanism for regeneration of photoisomerized (bleached)
visual pigments. Photoisomerization of 11-cis-retinal to all-
trans-retinal and reduction of the retinal to all-trans-retinol
occur in vertebrate photoreceptor cells. In adjacent retinal
pigment epithelium (RPE) cells, all-trans-retinol is esterified
with fatty acids to generate all-trans-retinyl esters. Enzymatic
isomerization  and  hydrolysis  of  the  ester  bond
(isomerohydrolase reaction) yields 11-cis-retinol and a fatty
acid. 11-cis-retinol is oxidized to 11-cis-retinal by one or more
cis-specific retinol dehydrogenases of RPE. The processes in
photoreceptor and RPE cells are coupled by directed flow of
11-cis-retinal  and  all-trans-retinol  across  the
interphotoreceptor  matrix  [1,2].  Evidence  leading  to  the
current understanding of the rod visual regeneration cycle has
been presented in reviews, to which the reader is referred
[3-9].
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Reactions of the rod cycle appear to be well established,
and the enzymes responsible for their catalysis have been
identified with the exception of the dehydrogenases, where
functional redundancies remain to be resolved. However, our
understanding of the interactions of components and of the
cell biology associated with retinoid trafficking in RPE and
photoreceptor cells remains rudimentary.
There  are  compelling  reasons  to  believe  that  cellular
retinaldehyde-binding protein (CRALBP) [10] is an important
component  of  the  rod  and  cone  visual  cycles  [11].  First,
CRALBP  has  a  very  high  affinity  for  11-cis-retinal  (Kd
approximately 15 nM) or 11-cis-retinol (Kd approximately 53
nM) [12,13] and carries these retinoids in vivo [14]. Second,
CRALBP is abundantly expressed in RPE and Müller cells
[15], two cell types implicated in rod and cone visual cycles.
Third, in vitro, CRALBP affected the kinetics of all reactions
of the rod visual cycle that involve 11-cis-retinoids including
those catalyzed by isomerohydrolase [16,17] and cis-retinol
dehydrogenase (RDH5) [12,18]. apoCRALBP was routinely
included in in vitro assays for isomerohydrolase because it
stimulated the rate of the reaction so dramatically [16,17].
Fourth, regeneration of rhodopsin was delayed by roughly 15-The high affinity of CRALBP for 11-cis-retinoids allows
the protein to accept 11-cis-retinol from isomerohydrolase of
the rod visual cycle and facilitate its oxidation to 11-cis-retinal
by cis-RDHs of RPE. However, this mechanism also leads to
an  apparent  dead  end  because  the  same  high  affinity  of
CRALBP  for  11-cis-retinal  has  to  date  prevented  an
experimental  demonstration  of  release  of  retinal  from  the
binding protein. Here we report that CRALBP bound to acidic
(anionic) glycerophospholipid surfaces with specificity, and
we identified a basic recess on a surface of the protein that
may  mediate  binding.  Using  an  assay  that  allowed  us  to
measure release of 11-cis-retinal from CRALBP, we found
that treatment of CRALBP with small unilamellar vesicles
(SUVs)  doped  with  acidic  glyceropholipids,  phosphatidic
acid (PA) and phosphatidylserine (PS) in particular, resulted
in release of 11-cis-retinal from the protein. These acidic
glycerophospholipids  are  the  first  discovered  physiologic
substances  that  release  tightly  bound  11-cis-retinal  from
CRALBP. It is particularly exciting that these minor lipids are
found  primarily  in  the  cytoplasmic  leaflets  of  the  plasma
membrane and intracellular vesicular membranes where they
could encounter CRALBP.
METHODS
Materials: Phospholipids and their sources were as follows:
dipalmitoyl  phosphatidic  acid  (PA;  Avanti  Polar  Lipids,
Alabaster, AL); PA, from egg yolk (Sigma Aldrich, St Louis,
MO);  phosphatidylcholine  (PC),  egg  yolk,  bovine  brain
(Sigma Aldrich); phosphatidylethanolamine (PE), from egg
yolk (Sigma Aldrich); phosphatidylserine (PS), bovine brain
(Sigma  Aldrich);  PI,  from  bovine  liver  (Sigma  Aldrich);
phosphatidylinositol-4-phosphate (PI(4)P), from bovine brain
(Calbiochem,  San  Diego,  CA  and  EMD  Biosciences,
Gibbstown,  NJ)  and  porcine  brain  (Avanti  Polar  Lipids);
phosphatidylinositol-4,5-bisphosphate  (PI(4,5)P2),  from
porcine  brain  (Avanti);  phosphatidylinositol-3,4,5-
trisphosphate  (PI(3,4,5)P3),  dioleoyl  (Avanti);
sphingomyelin, from bovine brain, egg yolk (Applied Science
Laboratories Inc., State College, PA); gangliosides (Type III,
G-2375, from bovine brain; Sigma Aldrich); sulfatides from
bovine spinal cord (Applied Science Laboratories). 11-cis-
Retinal was obtained through the generosity of the National
Eye Institute (Bethesda, MD). 9-cis-Retinal was purchased
from Sigma Aldrich. Methods for handling and analysis of
retinoids  have  been  published  [23].  Anti-CRALBP  was  a
polyclonal  antibody  (pAb  UW55)  isolated  from  rabbits
immunized with rCRALBP.
General: All work with light-sensitive materials (retinoids,
retinoid-binding proteins) was performed in red illumination
to  avoid  photoisomerization  and  photooxidation  of  the
retinoid. Air was removed from buffers by bubbling with
argon.
Preparation  of  CRALBP·9-cis-retinal,  CRALBP·11-cis-
retinal, and rCRALBP: CRALBP was purified from bovine
retina using a combination of ion exchange, lectin affinity, and
hydroxylapatite  chromatographies  and  conjugated  with  9-
cis- or 11-cis-retinal as described previously [24]. rCRALBP
was expressed in E. coli as a His-tagged protein, purified via
a Ni-affinity column, and conjugated with 9-cis-retinal.
Lipid-immunoblot  assay:  The  lipid-immunoblot  assay  we
employed is a variation on that described for determining the
specificity  of  pleckstrin  homology  domains  for
phosphoinositides [25]. Various glycerophospholipids were
dissolved in CHCl3 and small volumes (<5 μl, 5–25 nmol)
were applied to nitrocellulose membranes (Hybond ECL, GE
Healthcare,  Little  Chalfont,  Buckinghamshire,  UK)  with
drying. Afterwards, the membrane was incubated with 10 μg/
ml CRALBP in Tris-buffered saline Tween (TBST, 10 mM
Tris, pH 8, 0.15 M NaCl, 0.05% Tween-20). The membrane
was then washed with TBST containing 2% milk proteins
(from dried non-fat milk, Lucerne Dairies, Seattle, WA) and
incubated sequentially with anti-CRALBP (UW55 pAb), anti-
rabbit IgG coupled to alkaline phosphatase, and a luminescent
alkaline  phosphatase  substrate  (Lumi-Phos  WB  Pierce,
Thermo Fisher Scientific, Pittsburgh, PA). Milk protein was
included in the antibody solutions to reduce the background.
Blots were incubated with X-ray film for chemiluminescent
detection.  Controls  included  application  of  solvent  only,
omission of CRALBP, and substitution of other proteins for
CRALBP.
Assays for release of retinal from CRALBP: CRALBP has a
high affinity for 9-cis-retinal and 11-cis-retinal [12,13]. In
addition, the carbonyl of either retinal bound to CRALBP is
sequestered  from  reaction  with  water-soluble  carbonyl
reagents [18,26]. We exploited these properties to develop
assays for the release of retinal from CRALBP. Commercially
available 9-cis-retinal was used as a surrogate for 11-cis-
retinal in many of these studies, but all results have been
repeated with 11-cis-retinal. The spectral assay was based on
differences in the spectral properties of 9-cis-retinal, 9-cis-
retinal bound to CRALBP, and 9-cis-retinal oxime. The high
performance liquid chromatography (HPLC) assay involved
extraction  of  bound  retinoids  after  incubation  and
identification and quantification of cis-retinals and cis-retinal
oximes. These assays were performed in dim red illumination
to avoid photoisomerization of bound retinal.
Spectral  assay  for  release  of  retinal  from  CRALBP:
CRALBP·9-cis-retinal  or  CRALBP·11-cis-retinal  (6  or
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fold in mice lacking a functional CRALBP gene (Rlbp1−/−)
and analysis of rod visual cycle intermediates demonstrated a
delay at the isomerohydrolase step of the visual cycle [19].
Electroretinogram (ERG) analysis also demonstrated delays
in both rod and cone resensitization in these mice. Finally,
humans  with  mutations  in  the  CRALBP  gene  (RLBP1)
displayed  delays  in  resensitization  of  both  cone  and  rod
pathways [20-22].12 μM) in 20 mM MOPS, pH 7.2, was incubated at room
temperature  in  the  dark  with  2  mM  NH2OH  (freshly
neutralized  NH2OH·HCl).  SUVs  of  various  compositions
were added (90 μM total phospholipid concentration) and UV/
Vis spectra were recorded at intervals. The absorbances of 9-
cis-retinal and 11-cis-retinal are shifted from approximately
365 nm (hexane) to 410 nm and 425 nm, respectively, when
bound to CRALBP. Retinal oximes absorb at 355 nm. Thus,
the release of either retinal from CRALBP for reaction with
NH2OH was registered as a decrease in absorbance at 410 or
425 nm and an increase in absorbance at approximately 355
nm.
HPLC assay for release of retinal from CRALBP: Release of
9-cis-retinal  or  11-cis-retinal  from  CRALBP  was  also
monitored by extraction of the retinoids and quantification by
HPLC analysis. CRALBP·9-cis-retinal (12 μM) in 20 mM
MOPS, pH 7.2, was incubated with 2 mM NH2OH at room
temperature.  At  intervals,  portions  were  removed  and
incubated with pyridoxal 5′-phosphate to inactivate NH2OH.
After 10 min, ethanol was added to 50% (v/v), and retinoids
were  extracted  into  hexane  by  following  published
procedures. Retinoids were resolved and quantified with a
Phenomenex Luna 3 silica (2) column (150×4.6 mm, 3 μm)
and  isocratic  elution  with  hexane:  ethyl  acetate:  octanol
(90/10/1,  v/v).  Methods  used  for  extraction  and  retinoid
analysis  have  been  previously  described  [23].  After
incubation  of  CRALBP·9-cis-retinal,  an  additional  peak
appeared in the chromatogram, which migrated close to 9-
cis-retinal. We are uncertain of the identity of this component.
Its spectrum, obtained on the fly, was indistinguishable from
that  of  9-cis-retinal.  No  additional  oximes  appeared  upon
incubation with NH2OH.
Preparation of SUVs: The general method used was that of
Barenholz  et  al.  [27]  as  described  by  Fang  et  al.  [28].
Phospholipids (50 mg) were dissolved in CHCl3, dried with
flowing argon, resuspended in 3 ml of buffer, which contained
50 mM MOPS, pH 7.2, 100 mM KCl, 1 mM EGTA, and 1 mM
MgCl2. The mixture was then sonicated on ice with a micro
sonicator  probe  operated  at  70W  (Sonic  Dismembrator,
Model 100, Fischer Scientific) until the solution was clear.
Next,  0.1  mM  diethylenetriaminepentaacetic  acid  (DTPA)
was added to inhibit oxidative decomposition of lipids. SUVs
were  recovered  in  the  supernatant  after  centrifuging  at
60,000 ×g at 25 °C for 2 h.
CRALBP model structure: Coordinates for a molecular model
of  CRALBP  were  analyzed  with  molecular  visualization
software  RasMol  [29],  Chime,  MIFit  [30],  and  XtalView
[31]  to  examine  the  distribution  of  basic  residues  on  the
surface  of  the  protein.  Electrostatic  surface  potential  was
calculated and viewed using CCP4mg [32].
RESULTS
CRALBP bound to a select set of lipids: We were led to
examine whether CRALBP could bind to lipids because the
ligand-binding domain of the protein is derived from that of
yeast SEC14, a protein that mediates exchange of PI and PC
[33]. Various membrane lipids were dissolved in CHCl3 and
applied  to  nitrocellulose  membranes  in  small  spots  (5–25
nmol  lipid/spot).  After  nonspecific  binding  sites  were
blocked, the membrane was probed with CRALBP isolated
from  bovine  retina.  CRALBP  that  was  retained  on  the
membrane  was  detected  by  anti-CRALBP,  alkaline
phosphatase coupled to anti-IgG, and a chemiluminescent
substrate. Figure 1A illustrates the results obtained with some
lipids found in biologic membranes. In general, CRALBP
bound to acidic (anionic) lipids but even within this class there
was  considerable  variation  in  specificity.  PA,  a  dianionic
glycerophospholipid,  and  PI(3,4,5)P3,  a  polyanionic
glycerophospholipid, bound CRALBP avidly, as judged by
the intensity of staining with anti-CRALBP. The intensity of
staining with PS, PI(4)P, and PI(4,5)P2 was less than that
observed with PA and PI(3,4,5)P3 but well above background.
CRALBP did not bind to neutral (zwitterionic) lipids such as
Figure 1. Lipid-immunoblot assay. A: Several lipids were surveyed.
Lipids  were  dissolved  in  CHCl3  and  applied  to  nitrocellulose
membranes in small spots (25 nmol/spot). After the membrane was
appropriately blocked and washed, it was probed with bovine cellular
retinaldehyde-binding  protein  (CRALBP)  and  anti-CRALBP  as
described in Methods. CRALBP bound tightly to surfaces coated
with  the  acidic  glycerophospholipids,  phosphatidic  acid  (PA),
phosphatidylinositol-3,4,5-tris-phosphate  [PI(3,4,5)P3],
phosphatidylserine  (PS),  phosphatidyl-4-phosphate  (PI(4)P),  and
more  weakly  to  surfaces  coated  with  the  other  acidic  lipids
phosphatidylinositol  (PI),  phosphatidylinositol-4,5-bisphosphate
(PI(4,5)P2),  and  a  mixture  of  sulfatides  (Sulf).  No  binding  was
apparent with phosphatidylcholine (PC), phosphatidylethanolamine
(PE), sphingomyelin (SPH), or a mixture of gangliosides (Gang).
Each of the three columns in the figure was derived from a separate
immunoblot.  The  size  of  the  lipid  spots  was  variable  due  to
components  in  the  lipid  solutions  that  affected  wetting  of  the
nitrocellulose. The results shown are representative of at least three
independent analyses of each lipid. B: Active lipids were compared
on the same blot. The lipids indicated below the blot were applied to
nitrocellulose in small spots (25 nmol/spot) and probed with bovine
CRALBP  as  described  for  A.  The  order  of  staining  intensity
(PA>PS>PI>PC)  was  observed  in  at  least  three  independent
analyses. Solvent is abbreviated Sol.
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846PC, PE, and sphingomyelin or to a mixture of gangliosides. A
mixture of sulfatides showed weak binding. A comparison of
the binding of CRALBP to several lipids on the same blot is
shown in Figure 1B. Based on the intensity of staining, the
binding efficiency was PA>PS>PI>PC. CRALBP bound to
both  PA  isolated  from  natural  sources  and  to  synthetic
dipalmitoylPA, suggesting that the fatty acids esterified to
glycerol were not important determinants of binding (results
not shown). Apo-CRALBP and CRALBP·11-cis-retinol both
bound to PA and PS surfaces suggesting that bound retinoid
was not required for binding (results not shown). Further
studies were pursued with PA because this lipid has been
demonstrated  to  control  protein  binding  to  membranes
[34-37]  and  because  it  is  relatively  abundant  in  biologic
membranes [38].
Validation of assays for release of retinal from CRALBP:
Lack  of  release  of  the  chromophore  during  incubation  of
CRALBP·9-cis-retinal in the presence of NH2OH at neutral
pH and room temperature emphasized that the aldehyde group
of the retinoid was remarkably protected from the carbonyl
reagent.  When  4  M  urea  was  included  in  the  incubation
mixture, the absorption maximum of the bound retinal shifted
progressively from approximately 400 nm to approximately
355 nm and after 3 h of incubation the retinoid was nearly
completely recovered as 9-cis-retinal oxime (Figure 2A,B). In
the absence of urea, the absorption spectrum of the bound
retinoid was little affected during 3 h of incubation and >95%
of the chromophore was recovered as 9-cis-retinal and not as
the  oxime  (Figure  2C,D).  Incubation  of  CRALBP·9-cis-
retinal or 11-cis-retinal with NH2OH with various additives
such  as  glycerophospholipids  provided  the  basis  for  the
release assay to be described in subsequent experiments.
PA  released  9-cis-retinal  from  native  bovine  CRALBP:
CRALBP·9-cis-retinal was incubated with NH2OH and SUVs
using the conditions of the release assays. Incubation with
SUVs composed of 50 mol% PC and 50 mol% PA produced
spectral changes consistent with release of 9-cis-retinal for
reaction  with  NH2OH  (Figure  3A),  and  HPLC  analysis
verified increased recovery of 9-cis-retinal oximes after 18 h
(Figure 3B). The amount of retinal released in this experiment
was roughly 60% of that bound to CRALBP. SUVs composed
solely of PC had little effect on the absorption spectrum of 9-
Figure  2.  Validation  of  assays  for
release  of  cis-retinal  from  CRALBP.
Cellular  retinaldehyde-binding  protein
(CRALBP) ·9-cis-retinal (12 μM) was
incubated  in  the  dark  with  2  mM
NH2OH in the presence or absence of 4
M urea. Incubation of the protein with 4
M urea resulted in a progressive loss of
absorbance at 410 nm and an increase in
absorbance at 355 nm (A). The retinoid
was recovered by extraction and high
performance  liquid  chromatography
(HPLC) analysis as 9-cis-retinal oxime
(B).  During  60  min  of  incubation
without urea, there was minimal shift of
the  ligand  UV  absorption  maximum
(C).  The  retinoid  was  recovered  by
extraction and HPLC analysis as 9-cis-
retinal  and  an  unidentified  retinoid,
possibly a di-cis-retinal (D). The results
shown in the panels are representative of
at least six independent repeats of the
experiment.
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847cis-retinal bound to CRALBP (Figure 3C), and little 9-cis-
retinal oxime was recovered after 18 h of incubation (Figure
3D).  The  release  of  9-cis-retinal  was  comparable  to  that
observed during incubation of the binding protein in buffer
for  18  h  (result  not  shown)  and  is  likely  due  to  thermal
instability of the protein.
Specificity of release of 11-cis-retinal and 9-cis-retinal from
CRALBP: To explore the specificity of release, we incubated
6 μM CRALBP·11-cis-retinal with 2 mM NH2OH and SUVs
of varying compositions (Figure 4A) for a total phospholipid
concentration of 90 μM. After 16 h at room temperature,
retinoids were extracted and quantified by HPLC. The amount
of 11-cis-retinal oximes (syn + anti) was indicative of the
release of 11-cis-retinal for reaction with NH2OH during the
incubation. The order of release activity from this experiment
was the same as that derived from the lipid-immunoblot assay
(PA>PS>>PI~PC; Figure 2). As with the binding assay, PC
and  PE  showed  minimal  activity.  We  also  employed  the
spectral  assay  to  determine  the  relative  order  of  release
resulting from incubation of CRALBP·9-cis-retinal with SUV
for 3 h (Figure 4B). The same order of release was observed
with a more limited set of lipids (PA>PS>PC).
Concentration dependence of release: CRALBP·9-cis-retinal
(6 μM) was incubated under release assay conditions with
SUVs composed of PC and various mol% of PA for a total
concentration of 90 μM lipid. The results shown in Figure 5
indicate that the extent of release was proportional to the mol
% of PA in the SUV over the range of compositions examined.
Model of CRALBP structure shows a cluster of basic amino
acid side chains: The crystal structures of four members of
the CRAL_TRIO family of proteins were used to construct
structural  models  of  CRALBP  [38,39].  The  electrostatic
surface potentials of two faces of CRALBP were calculated
and are shown in Figure 6. On one face of the model (Figure
6A, blue residues), a basic recessed area was immediately
obvious between upper and lower lobes of the protein. Basic
residues lining this recess were K103, K152, K258, K260,
R97,  R100,  R102,  R108,  R150,  R152,  and  H235.  The
diameter  of  the  recess  was  approximately  10  Å.  A  lipid-
exchange  loop  (CRALBP  residues  141–152,  Figure  6A),
which has been suggested to regulate the release of bound
ligand from the protein [40-42], is outlined in the upper left
quadrant of Figure 6A. Three amino acids conserved in the
CRAL_TRIO  family  (RAR,  CRALBP  residues  100–102,
Figure  3.  9-cis-Retinal  was  released
from  CRALBP  by  acidic
glycerophospholipids.  Cellular
retinaldehyde-binding  protein
(CRALBP)·9-cis-retinal was incubated
in  the  dark  with  NH2OH  and  small
unilamellar vesicles (SUVs). Release of
9-cis-retinal  was  followed  using  the
spectral assay (A and C) and the HPLC
assay  (B  and  D).  Incubation  of
CRALBP·9-cis-retinal  with  SUVs
composed  of  50  mol%
phosphatidylcholine (PC) and 50 mol%
phosphatidic  acid  (PA)  produced
spectral changes over 18 h consistent
with release of 9-cis-retinal for reaction
with NH2OH (A), and high performance
liquid chromatography (HPLC) analysis
of  an  18  h  sample  demonstrated
recovery  of  9-cis-retinal  oximes  (B).
Incubation with SUVs composed of 100
mol%  PC  had  little  effect  on  the
absorption  spectrum  of  9-cis-retinal
bound to CRALBP (C), and minimal
amounts  of  9-cis-retinal  oximes  were
recovered  (D).  The  amount  of  9-cis-
retinal released in A was approximately
60% of the total bound to the protein. In
B and D, only the oxime regions of the
chromatograms  are  shown.  The  data
shown in the panels are representative of
at least five independent repeats of the
experiment.
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848Figure 4. Release of 11-cis- and 9-cis-retinal from CRALBP. A:
Cellular retinaldehyde-binding protein (CRALBP)·11-cis-retinal (6
μM)  was  incubated  in  the  dark  with  2  mM  NH2OH  and  small
unilamellar vesicles (SUVs). The total phospholipid concentration
was  90  μM,  and  SUVs  were  composed  of  100  mol%
phosphatidylcholine (PC) or 50 mol% PC and 50 mol% other lipids,
as indicated. After 16 h at room temperature, retinoids were extracted
and quantified by high performance liquid chromatography. The
amount of 11-cis-retinal oximes (syn+anti) reflected the release of
11-cis-retinal for reaction with NH2OH during the incubation. The
amount of 11-cis-retinal released from by PC: phosphatidic acid (PA)
was approximately 75% of the total bound to CRALBP. The results
shown are from a single experiment. B: CRALBP·9-cis-retinal (6
μM) was incubated in the dark with NH2OH and SUVs as described.
Spectra were obtained before and 3 h after addition of the SUVs. The
results are shown as the % of the maximum spectral change resulting
from  incubation  with  4  M  urea.  Error  bars  shown  are  standard
deviations  from  the  means  (n=3).  The  abbreviations  used  are:
phosphatidic  acid  (PA);  phosphatidylcholine  (PC);
phosphatidylethanolamine  (PE);  phosphatidylinositol  (PI);
phosphatidylserine (PS).
lower outlined cluster) are present in proximity to the rim of
the basic recess. These residues have been suggested to play
a role in regulation of access to the ligand-binding cavity. An
acidic patch located below the ligand-exchange helix (Figure
6B, red) characterized another face of the protein.
DISCUSSION
Previous in vitro studies provided mechanisms for loading
apo-CRALBP with 11-cis-retinol [16,17] and for oxidation of
CRALBP·11-cis-retinol to CRALBP·11-cis-retinal [18,26]. If
11-cis-retinoids flow through the binding site of CRALBP, as
these findings imply, a subsequent step must involve release
of  the  11-cis-retinal  from  the  binding  protein  to  another
component, to the exterior of the RPE cell, or possibly to the
interior  of  a  recycling  vesicle.  However,  incubation  of
CRALBP·11-cis-retinal  with  numerous  putative  acceptors,
cofactors, as well as RPE tissue fractions did not release retinal
from the protein. For instance, 11-cis-retinal was not released
from  CRALBP  during  incubation  with  RPE  microsomes
±3 mM ATP, RPE microsomes±0.1 mM reduced glutathione/
Figure 5. Release of retinal as a function of PA content of SUVs.
CRALBP×9-cis-retinal  (6  μM)  was  incubated  with  NH2OH  and
SUVs  composed  of  PC  and  varying  amounts  of  PA  (total
glycerophospholipid 90 μM). The mole % of PA in the SUVs in
indicated  on  the  abscissa.  After  incubation  for  16  h  at  room
temperature in the dark, retinoids were extracted and quantified by
HPLC  analysis.  The  results  shown  are  representative  of  two
independent repeats of the experiment.
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8491  mM  oxidized  glutathione,  RPE  microsomes
±interphotoreceptor  retinoid-binding  protein  (IRBP;
equimolar  with  CRALBP),  proteases  (matrix
metalloproteinases  2  or  9),  and  anti-CRALBP  (threefold
molar excess; Garwin and Saari, results not shown). CRALBP
is  an  eponymous  member  of  the  CRAL_TRIO  family  of
proteins whose lipid-binding domain was derived from that of
the yeast SEC14 protein [32]. SEC14 mediates transfer of PC
and PI between Golgi and plasma membranes and is necessary
for  secretion  in  yeast.  Thus,  the  evolutionary  origins  of
CRALBP led us to consider whether glycerophospholipids
might be capable of releasing 11-cis-retinal from the protein.
The  lipid-immunoblot  assay  employed  in  this  study
clearly demonstrated that CRALBP bound to a select set of
lipid surfaces. Specificity was evident at two levels. First, of
the lipids tested, CRALBP only bound to acidic lipids. This
eliminated the possibility that binding was an artifact caused
by denaturation of CRALBP on the lipid surface. Second,
CRALBP bound to some acidic lipids more avidly than to
others  with  an  apparent  order  of  binding  affinity  PA  >
PI(3,4,5)P3 > PS. This suggested that binding was mediated
by spatial recognition and not simply by the charge of the lipid.
It is all the more remarkable that CRALBP binds to acidic
surfaces because its overall charge is acidic at neutral pH (pI
~5).
Incubation of CRALBP·11-cis-retinal with SUVs of PC
plus other glycerophospholipids demonstrated specificity for
release of 11-cis-retinal. As observed in the binding assay, PA
was the most effective lipid of those we tested in releasing 11-
cis-retinal from CRALBP. The order of efficacy for release
Figure 6. Electrostatic surface potential
of CRALBP. The structural model of
cellular  retinaldehyde-binding  protein
(CRALBP; PDB entry 1XGH) is that of
Liu et al. [40]. Surface regions in red
have negative electrostatic potential and
are acidic. Those in white have neutral
electrostatic potential and those in blue
have positive electrostatic potential and
are basic. A: The two frames form a
stereo pair of the basic face of CRALBP.
The  basic  recess  (blue)  between  the
upper and lower lobes of CRALBP is
approximately  10  Å  in  diameter.  An
Arg-Ala-Arg  (RAR)  sequence,
conserved throughout the CRAL_TRIO
protein family, is shown (small patch of
circled residues). The retinoid-binding
site  is  covered  by  the  lipid  exchange
loop (large patch of circled residues).
The  basic  recess  may  mediate
interactions of CRALBP with specific
acidic lipids. B: The two images form a
stereopair  of  the  acidic  face  of  the
protein. Note the (negative) acidic patch
(red).
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850matched the order of effectiveness of binding to lipid surfaces,
suggesting  that  the  release  mechanism  may  be  related  to
binding of CRALBP to anionic lipids in the SUV. However,
other mechanisms are possible as discussed in this section,
including direct binding of the lipid in the 11-cis-retinal–
binding site. It should also be noted that the lipid-blot assay
we employed is qualitative and many parameters remain to be
established.  For  instance,  retention  of  the  lipids  on  the
nitrocellulose membrane during washings and incubations
could vary from lipid to lipid and the state of the lipid adsorbed
to the membrane has not been characterized. Nonetheless, the
results were useful in identifying lipids that were active in
releasing 11-cis-retinal from CRALBP.
The acidic glycerophospholipids we identified here are
the  first  physiologic  compounds  found  that  affected  the
affinity of CRALBP for 11-cis-retinal. Which one, if any, of
the  acidic  glycerophospholipids  is  relevant  in  RPE  cells
remains to be determined. Phosphoinositides are important in
mammalian  signaling  because  their  synthesis  can  be
stimulated and because they can be recognized by various
protein motifs [38]. However, in most membranes they are
minor lipids (<0.1 mol%) and would appear poorly suited for
stoichiometric  processes.  For  instance,  the  level  of
PI(3,4,5)P3, the most active phosphoinositide in our study, is
0.005 to 0.0005 that of PI [38,43]. In contrast, PS and PA are
the  main  acidic  phospholipids  of  mammalian  cells.
Concentrations  of  PS  in  the  inner  leaflet  of  the  plasma
membrane can reach 25 mol% [38]. PA, in particular, has
recently attracted a great deal of attention because of its unique
properties [34,35,44]. Localization in the cytoplasmic leaflet
of the plasma membrane [38] and generation in response to
activation  of  various  signaling  pathways  [37,45]  provide
rationales for its ability to control the activity or subcellular
localization of various proteins [46,47].
Models of CRALBP structure show a cluster of basic
residues  on  a  face  of  the  protein  adjacent  to  the  “ligand
exchange helix.” Binding of the protein to acidic lipid surfaces
may occur via this patch, a hypothesis that can be tested
through site-generated mutagenesis. It is interesting to note
that several disease-causing missense mutations involve basic
residues  (R150Q,  R150W,  R233W,  R234W/R103W
compound heterozygote) [48]; however, of these only R150
appears to contribute to the basic recess. We do not understand
the significance of the acidic patch on another face of the
protein (Figure 6B). However, its presence emphasizes the
nonrandom  distribution  of  acidic  and  basic  residues  and
further  suggests  that  CRALBP  might  interact  with  other
proteins or substances via this acidic patch.
Two  mechanisms  for  release  of  11-cis-retinal  appear
likely. 1) Direct binding of the acidic glycerophopholipid in
the  11-cis-retinal  binding  pocket  should  be  considered
because the ligand-binding domain of CRALBP is derived
from the glycerophospholipid-binding domain of SEC14. It is
possible  that  CRALBP  has  retained  some  of  the
gycerophospholipid-binding properties of its ancestor. In this
mechanism,  dissociation  of  11-cis-retinal  from  CRALBP
would be followed by binding of the acidic lipid. However,
the mechanism implies that the acidic lipid has an affinity for
the protein equal to or greater than that of 11-cis-retinal and
CRALBP, purified from RPE homogenates in the absence of
exogenous retinoid, was nearly completely saturated with 11-
cis-retinal  [14]  even  though  the  homogenates  contained
Figure  7.  Hypothesis  for  release  of
retinal  by  glycerophospholipids.
Cellular  retinaldehyde-binding  protein
(CRALBP) binds to sodium hydrogen
exchanger  regulatory  factor  type  1
(NHERF1)  via  interactions  with  post
synaptic density 95-discs large-zonula
occludens (PDZ1), and perhaps PDZ2
[9,51,52]. NHERF1 binds to ezrin, an
actin-binding  scaffold  protein.
NHERF1, ezrin, actin, and CRALBP are
found  in  retinal  pigment  epithelium
apical  processes.  We  suggest  that
binding of CRALBP to this or a similar
complex  restricts  the  diffusion  of
CRALBP  in  the  vicinity  of  acidic
glycerophospholipids  of  the  inner
leaflet  of  the  plasma  membrane  or
perhaps a vesicular membrane. Image
modified from Nawrot et al. [52].
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851abundant amounts of glycerophospholipids. Determination of
the amount of radioactivity associated with CRALBP after
incubation with PC-SUVs doped with [14C] PA should resolve
this issue. 2) It is also possible that the ligand-binding domain
of CRALBP is perturbed when CRALBP binds to acidic lipids
in SUVs experimentally or the plasma membrane in vivo,
resulting in diminished affinity and release of the ligand. The
basic  recess  of  CRALBP  appears  immediately  below  the
ligand-binding  domain  of  the  protein  (Figure  6A).
Neutralization of the basic charges on the protein by acidic
lipids could be followed by a structural rearrangement, which
would decrease the affinity of CRALBP for 11-cis-retinal. A
first step in analyzing this mechanism would be to determine
whether CRALBP binds to SUVs or other suitable membrane
surrogates doped with acidic glycerophospholipids.
The role of the SUVs in these release experiments has not
yet been established. They could mimic a membrane surface
and provide a docking site for CRALBP via an acidic lipid as
discussed in the previous section. Alternatively, the SUVs
could simply provide a vehicle for solubilization of PA or
other acidic lipids, which could then bind to CRALBP in the
basic  recess  or  in  the  retinoid-binding  site.  The  average
number of glycerophospholipids/SUV is approximately 2,300
[49].  Thus,  the  SUV  concentration  in  our  experiments
(90  μM  ÷  2300)  is  39  nM—154  fold  lower  than  the
concentration  of  CRALBP·9-cis-retinal.  This  rules  out  a
mechanism involving stoichiometric binding of CRALBP to
an SUV unless the complex dissociates after release of the
retinal. However, the results appear consistent with the SUVs
simply solubilizing PA or another acidic lipid and delivering
the lipid to CRALBP. Even at 10 mol%, the lowest mol% of
PA in the SUVs, the input concentration of PA is greater than
the concentration of CRALBP·9-cis-retinal. Results from the
additional  experimental  approaches  to  the  mechanism  are
needed to decide the issue.
It is clear from these studies that PA and other acidic
lipids release 11-cis-retinal from CRALBP. However, there
are  many  other  naturally  occurring  acidic  substances  that
could also be active, including fatty acids, acidic peptides, or
acidic  motifs/domains  of  other  proteins.  Further
experimentation is necessary to determine the potential roles
of these substances.
The rate of release of 11-cis-retinal from CRALBP in the
experiments described here appears to be too slow for the
process to be a factor in a physiologic mechanism. In addition,
the 50 mol% PA used in most of the experiments here is much
higher  than  reported  in  naturally  occurring  membranes.
However,  it  is  possible  that  mechanisms  exist  in  vivo  to
accelerate the rate of release with a lower concentration of PA.
For instance, we noted that 9-cis-retinal was released much
more rapidly by PA from rCRALBP than from the native
protein (t1/2 approximately 30 min compared to several hours,
respectively; results not shown). rCRALBP has a sequence of
nine histidines at its N-terminus [50], which could bind to PA-
doped SUVs and increase the concentration of PA in the
vicinity of the basic recess or ligand-binding domain. Previous
studies  have  established  that  CRALBP  binds  to  the  post
synaptic  density95-discs  large-zonula  occludens  (PDZ)-
domain protein sodium-hydrogen exchanger regulatory factor
type 1 (NHERF1) via interactions with PDZ1 and perhaps
PDZ2 [51,52]. NHERF1 in turn, can bind to ezrin, an actin-
binding scaffold protein [53]. All of these components are
found in RPE apical processes [50]. Formation of a complex
with  CRALBP,  NHERF1,  ezrin,  and  actin  in  RPE  apical
processes  could  increase  the  concentration  of  the  binding
protein  in  the  vicinity  of  the  inner  leaflet  of  the  plasma
membrane and thus increase the rate of release of 11-cis-
retinal  (Figure  7).  This  hypothesis  could  be  approached
experimentally by determining whether PA released 11-cis-
retinal from CRALBP in isolated complexes with NHERF1,
or NHERF1 and ezrin [52].
In summary, we have demonstrated that CRALBP bound
strongly to PA and more weakly to a restricted set of acidic
lipids. PA, presented as a component of an SUV, released 11-
cis- or 9-cis-retinal from CRALBP more effectively than any
other of the major acidic lipids tested and in general, the order
of efficacy for release matched that for binding. A recess lined
with  basic  (positively  charged)  residues  was  found  on  a
surface of a model of CRALBP and could mediate binding of
acidic (negatively charged) lipids and their ability to release
11-cis-retinal.  Acidic  glycerophospholipids  are  the  first
naturally occurring substances discovered that release 11-cis-
retinal from CRALBP.
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